Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A

Cytotechnology. 1992;10(1):75-89. doi: 10.1007/BF00376102.

Abstract

A 300-fold adriamycin resistant variant (DLKP-A) of the human lung squamous cell carcinoma line DLKP was established by stepwise selection in increasing concentrations of adriamycin. Different levels of cross-resistance were observed towards VP-16, VM-26, colchicine, vincristine and, somewhat unexpectedly, cis-platin. Resistance was stable for at least 3 months in culture in the absence of drug. P-glycoprotein overexpression was detected by immunofluorescence and Western Blotting, and a direct causal role for P-glycoprotein overexpression in the resistant phenotype was established by transfection with an mdr1 specific antisense oligonucleotide. A modified cryopreservation procedure was necessary for the resistant variant line. The resistant population displays clonal heterogeneity with respect to resistance level. A higher frequency of double minute chromosomes was observed in DLKP-A when compared with the parental cell line.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Base Sequence
  • Blotting, Western
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Chromosome Banding
  • Culture Techniques / methods
  • Doxorubicin / pharmacology*
  • Drug Resistance / genetics*
  • Fluorescent Antibody Technique
  • Genetic Variation
  • Glycoproteins / analysis
  • Glycoproteins / biosynthesis
  • Glycoproteins / genetics
  • Humans
  • Lung Neoplasms / genetics*
  • Male
  • Metaphase
  • Middle Aged
  • Molecular Sequence Data
  • Oligonucleotides, Antisense
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Glycoproteins
  • Oligonucleotides, Antisense
  • Doxorubicin